所有图片(1)
选择尺寸
变更视图
200 MG
$627.00
About This Item
经验公式（希尔记法）:
C10H16N2O4S3 · HCl
CAS号:
分子量:
360.90
Beilstein:
5896026
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
推荐产品
等級
pharmaceutical primary standard
API 家族
dorzolamide
製造商／商標名
USP
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
Cl.CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O
InChI
1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1
InChI 密鑰
OSRUSFPMRGDLAG-QMGYSKNISA-N
基因資訊
human ... CA2(760)
正在寻找类似产品? 访问 产品对比指南
相关类别
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Dorzolamide hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution
- Dorzolamide Hydrochloride Ophthalmic Solution
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral - STOT RE 2
標靶器官
Central nervous system,Gastrointestinal tract,Bone,Blood,Bladder
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
M F Sugrue
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 12(3), 363-376 (1996-01-01)
Dorzolamide hydrochloride (S,S-5,6-dihydro-4H-4-ethylamino-6-methylthieno [2,3-b]thiopyran-2-sulfonamide-7,7-dioxide HCl; MK-507; L-671,152) is a water-soluble, potent inhibitor of human carbonic anhydrase isoenzymes II and IV in vitro, the respective IC50 values being 0.18 nM and 6.9 nM. In contrast, it was found to be a
Göktuğ Seymenoğlu et al.
Journal of glaucoma, 24(2), 111-116 (2013-06-29)
To compare the efficacy of fixed combinations of dorzolamide-timolol (FCDT) and brimonidine-timolol (FCBT) in patients with intraocular pressure (IOP) elevations after intravitreal triamcinolone acetonide (IVTA) injections. This was a prospective, randomized, open-label study. Patients who received IVTA injections due to
Azza A Hasan
Pharmaceutical development and technology, 19(6), 748-754 (2013-08-24)
The objective of this work was to formulate and characterize non-ionic surfactant vesicles (niosomes) as an ocular carrier of dorzolamide hydrochloride (Dorzo); one of the antiglaucoma drugs. Niosomes were prepared of Cholesterol (Chol) with sorbitan monoesters (Span 20, 40, 60)
Masamichi Fukuda et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 31(1), 57-60 (2014-10-11)
We investigated the transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes. One drop (30 μL) of each ophthalmic solution (Xalacom(®), DuoTrav(®), Cosopt(®), and Timoptol(®)) was administered to the conjunctival sac of the rabbits' eyes and the
Active Filters
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门
